REGENXBIO
@REGENXBIO
Followers
2K
Following
70
Media
378
Statuses
684
REGENXBIO is dedicated to transforming the lives of people suffering from severe diseases with significant unmet medical need through our NAV® gene therapy.
Rockville, MD
Joined February 2016
Happy Independence Day! Wishing you a safe and celebratory holiday.
0
0
2
At our recent all-company meeting, we announced our CEO Award winner, Leiby Soto! Leiby is a true connector—someone who brings people together and helps create a culture where everyone feels like they belong. Join us in celebrating Leiby for this well-deserved recognition!
0
0
1
We’re excited to share that REGENXBIO has been recognized as a 2025 Washington Post Top Workplaces winner — our fourth time participating in the survey and our fourth win!. Thank you to our entire team for making REGENXBIO such a special place to work!
0
0
3
Our team enjoyed attending the 2025 @IAmBiotech Innovation Organization International Convention this week in Boston! Our VP of Regulatory and Corporate Strategy, Nina Hunter, joined a panel of industry experts to discuss the future of early drug development.
1
0
2
Our team hit the streets of Philadelphia for the 12th Annual Million Dollar Bike Ride! @ODC_UPenn hosts this great event every year and has raised over $22 million. Our REGENXBIO riders always look forward to this opportunity to show our support for the rare disease community.
0
0
2
This #FathersDay, we honor the dads who are not only caregivers—but powerful advocates. Whether navigating a diagnosis, pushing for progress, or standing up for their children and loved ones, your strength and determination help drive change. Happy Father’s Day!
0
1
2
This past weekend, a group of fearless REGENXBIO team members took on the Great Chesapeake Bay Swim in support of the @JettFoundation! We're proud to support families impacted by Duchenne—thank you, Jett Foundation, for all you do!
0
0
1
Last week, we hosted our 4th annual Science Showcase—featuring a symposium and poster session highlighting the innovation and collaboration driving our AAV Therapeutics. Thanks to our teams for your passion and impact. What we do truly matters.
0
0
1
Today we announced new positive interim functional data from our Phase I/II AFFINITY DUCHENNE trial of RGX-202. Learn more: $RGNX
0
5
16
Welcome, REGENXBIO Summer Intern Class of 2025! We're thrilled to have this talented group join us and bring fresh perspectives, curiosity and energy. This summer, they'll be learning from our team of experts who are on a mission to improve lives through gene therapy.
0
0
2
Today, we announced that we will be hosting a webcast to discuss new interim functional data from the Phase I/II AFFINITY DUCHENNE trial of RGX-202, our next-generation investigational gene therapy for the treatment of Duchenne. Learn more:
0
0
5
Thank you to @CureDuchenne for another impactful conference! The conference was both inspiring and productive – highlighting the critical role of innovation and collaboration in advancing progress for those affected by Duchenne. #CureDuchenne #2025FUTURES
0
0
4
On this Memorial Day, we honor those who have served and sacrificed to protect our nation.
0
0
1
At REGENXBIO, all of our team members play an important role in advancing new medicines for patients. Hear from Juan Carlos Ramos, Manager of Manufacturing Operations about how our capabilities set us apart.
0
0
5
We look forward to connecting with the Duchenne community at @CureDuchenne's annual FUTURES National Conference in San Antonio, Texas! Thank you to the team at CureDuchenne for hosting another great conference to bring the community together to empower and support families.
0
0
1
Today, we announced the closure of a strategic, non-dilutive royalty monetization agreement of up to $250 million to accelerate the development of new gene therapies for patients. Learn more: $RGNX
0
0
12
REGENXBIO is at @ASGCTherapy this week, the premier gene therapy conference, showcasing our expertise from preclinical research to commercial-ready manufacturing. Hear from our CSO, Olivier Danos, Ph.D., as he reflects on the science and innovation driving our work.
0
0
4
Today we announced an exciting milestone in our mission to deliver a new treatment option for MPS II. Learn more about the FDA’s acceptance of the BLA for RGX-121, a potential one-time gene therapy for the treatment of MPS II: $RGNX
0
3
20
REGENXBIO reports first quarter 2025 financial results and recent operational highlights. $RGNX Learn more:
1
0
6
This Mother's Day, we celebrate the mothers who champion the patients in their lives – those who are caretakers and advocates, standing strong through uncertainty and inspiring breakthroughs that can change lives. Wishing you a Happy Mother's Day from all of us at REGENXBIO!
0
0
4